Is cannabidiol hepatotoxic or hepatoprotective: A review
Authors:
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Toxicology Research and Application
- Vol. 4
Abstract
Questions have been raised regarding the potential hepatotoxicity of cannabidiol (CBD). Conversely, several animal studies have demonstrated the hepatoprotective effects of CBD against bile duct ligation, cocaine, thioacetamide, alcohol, and several other chemicals. This review summarizes the current literature concerning the hepatic effects of CBD in humans and animals. Based on the available data, it may be concluded that there is a low probability of serious hepatotoxicity at the high therapeutic doses that are used and a much lower risk of adverse hepatic effects and a potential for hepatoprotection effects at the lower doses commonly used in dietary supplements and food products. However, a detailed safety study in rats using highly purified CBD rather than enriched Cannabis extracts is needed, enabling the determination of hepatic as well as other tissue effects and potential margin of safety.Keywords
Funding Information
- Boston Biopharm, Inc., Southlake, TX (NA)
This publication has 27 references indexed in Scilit:
- Cannabidiol Adverse Effects and ToxicityCurrent Neuropharmacology, 2019
- A systematic review of cannabidiol dosing in clinical populationsBritish Journal of Clinical Pharmacology, 2019
- Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse ModelMolecules, 2019
- Long‐term cannabidiol treatment in patients with Dravet syndrome: An open‐label extension trialEpilepsia, 2018
- Efficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-AnalysisDrugs, 2018
- Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New AgeFrontiers in Immunology, 2018
- Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromesEpilepsy & Behavior, 2018
- Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut SyndromeNew England Journal of Medicine, 2018
- Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet SyndromeNew England Journal of Medicine, 2017
- Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trialThe Lancet Neurology, 2016